Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Celgene Receives European Commission Approvals for Revlimid and Imnovid-Based Triplet Combination Regimens for Multiple Myeloma

Celgene Corporation announced that the European Commission approved two new triplet regimens based on the company’s proprietary IMiD treatments, Revlimid (lenalidomide) and Imnovid (pomalidomide).

Read More »

Novartis data at AAN show Gilenya is only disease-modifying therapy with proven superiority versus glatiramer acetate in RRMS

Novartis announced the full data of the ASSESS study, which evaluated the efficacy of oral, once-daily Gilenya (fingolimod) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of glatiramer acetate 20mg in reducing disease activity over 12 months in patients with relapsing remitting multiple sclerosis (RRMS).

Read More »

AstraZeneca Halts Phase III CLL Trial Early After Primary Endpoints Are Met

AstraZeneca’s Calquence (acalabrutinib) hit the mark in a Phase III trial of previously treated patients with chronic lymphocytic leukemia (CLL).

Read More »

Pfizer gets U.S. approval for $225,000 a year heart drug

The U.S. Food and Drug Administration approved Pfizer Inc.’s oral drug tafamidis to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy.

Read More »

GSK Cuts Flu and Pneumonia Vaccines After Disappointing Data

In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.

Read More »

AACE Meeting: New Data from Phase 3 OPTIC Study

Horizon Pharma announced that new data from the Phase 3 confirmatory study evaluating teprotumumab for treating active thyroid eye disease were presented as part of a late-breaking oral presentation at the 2019 AACE Scientific and Clinical Congress.

Read More »

Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Cornerstone

Six months after forging a hepatitis B drug development deal valued at more than $3.7 billion with Arrowhead Pharmaceuticals, Janssen Pharmaceutical presented data that showed the RNA interference (RNAi) therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.

Read More »

Janssen Presents Landmark Data From Invokana Study

Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.

Read More »

Janssen Presents New Data From First Phase 3 Trial Of Single-Tablet Regimen In Rapid Initiation Model Of Care Demonstrating Safety, Efficacy With Symtuza Through 48 Weeks

The Janssen Pharmaceutical Companies of Johnson & Johnson unveiled new 48-week data for Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg D/C/F/TAF) showing that a high proportion of HIV patients achieved an undetectable viral load through 48 weeks after rapidly starting Symtuza.

Read More »

ViiV Healthcare Announces 3-Year HIV Data for Juluca 2-Drug Combo

ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom